Skip to main content
SpringerLink
Log in

Metabolic Liver Disease: Part 1

  • Chapter
  • First Online:
Diseases of the Liver in Children

  • 1843 Accesses

Abstract

The liver is known to have an expansive role in the synthesis, degradation, and regulation of pathways involved in the metabolism of carbohydrates, proteins, lipids, trace elements, and vitamins. Subsequently, abnormalities that affect these pathways as well as specific enzyme deficiencies often affect the liver either primarily or secondarily. The spectrum of liver injury results when there is absence or blockage of an enzyme in the metabolic pathway often resulting in accumulation of unmetabolized toxic substrates and/or deficiencies in essential substances normally produced distal to the dysfunctional enzyme. Clinical presentations of children with metabolic liver disease vary from acute, life-threatening illness in the neonatal period to a more indolent, chronic disease process that becomes evident in adolescence or adulthood. Disease progression often results from the failure of metabolic functions resulting in hepatocyte injury or cellular derangement and hepatomegaly with advancement to cirrhosis and/or tumor development. A detailed history can often elicit the possibility of a metabolic dysfunction and assist in the guidance of further clinical investigations while treatment is dependent of the particular metabolic defect that is identified.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Suchy FJ, Sokol RJ, Balistreri WF. Liver disease in children. 3rd ed. Cambridge/New York: Cambridge University Press; 2007.

    Book  Google Scholar 

  2. Beutler E, Baluda MC, Sturgeon P, Day R. A new genetic abnormality resulting in galactose-1-phosphate uridyltransferase deficiency. Lancet. 1965;1:353–4.

    Article  PubMed  CAS  Google Scholar 

  3. Kawade N, Onishi S. The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem J. 1981;196:257–60.

    PubMed  CAS  PubMed Central  Google Scholar 

  4. Ridel KR, Leslie ND, Gilbert DL. An updated review of the long-term neurological effects of galactosemia. Pediatr Neurol. 2005;33:153–61.

    Article  PubMed  Google Scholar 

  5. Arias IM, Gartner LM, Seifter S, Furman M. Prolonged neonatal unconjugated hyperbilirubinemia associated with breast feeding and a steroid, pregnane-3(alpha), 20(beta)-diol, in maternal milk that inhibits glucuronide formation in vitro. J Clin Invest. 1964;43:2037–47.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Poland RL, Schultz GE, Garg G. High milk lipase activity associated with breast milk jaundice. Pediatr Res. 1980;14:1328–31.

    Article  PubMed  CAS  Google Scholar 

  7. Schneider 2nd AP. Breast milk jaundice in the newborn. A real entity. JAMA. 1986;255:3270–4.

    Article  PubMed  Google Scholar 

  8. Maisels MJ, Newman TB. Kernicterus in otherwise healthy, breast-fed term newborns. Pediatrics. 1995;96:730–3.

    PubMed  CAS  Google Scholar 

  9. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999;103:6–14.

    Article  PubMed  CAS  Google Scholar 

  10. Waggoner DD, Buist NR, Donnell GN. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis. 1990;13:802–18.

    Article  PubMed  CAS  Google Scholar 

  11. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, De Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med. 1995;333:1171–5.

    Article  PubMed  CAS  Google Scholar 

  12. Crigler Jr JF, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics. 1952;10:169–80.

    PubMed  Google Scholar 

  13. Van Der Veere CN, Sinaasappel M, Mcdonagh AF, Rosenthal P, Labrune P, Odievre M, Fevery J, Otte JB, Mcclean P, Burk G, Masakowski V, Sperl W, Mowat AP, Vergani GM, Heller K, Wilson JP, Shepherd R, Jansen PL. Current therapy for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology. 1996;24:311–5.

    Article  PubMed  Google Scholar 

  14. Wolkoff AW, Wolpert E, Pascasio FN, Arias IM. Rotor’s syndrome. A distinct inheritable pathophysiologic entity. Am J Med. 1976;60:173–9.

    Article  PubMed  CAS  Google Scholar 

  15. Cross NC, De Franchis R, Sebastio G, Dazzo C, Tolan DR, Gregori C, Odievre M, Vidailhet M, Romano V, Mascali G, et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. Lancet. 1990;335:306–9.

    Article  PubMed  CAS  Google Scholar 

  16. Stanbury JB. The metabolic basis of inherited disease. 5th ed. New York: McGraw-Hill; 1983.

    Google Scholar 

  17. Mayatepek E, Hoffmann B, Meissner T. Inborn errors of carbohydrate metabolism. Best Pract Res Clin Gastroenterol. 2010;24:607–18.

    Article  PubMed  CAS  Google Scholar 

  18. Saudubray JM, Sedel F, Walter JH. Clinical approach to treatable inborn metabolic diseases: an introduction. J Inherit Metab Dis. 2006;29:261–74.

    Article  PubMed  Google Scholar 

  19. Hiraiwa H, Pan CJ, Lin B, Moses SW, Chou JY. Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b. J Biol Chem. 1999;274:5532–6.

    Article  PubMed  CAS  Google Scholar 

  20. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002;161 Suppl 1:S20–34.

    PubMed  CAS  Google Scholar 

  21. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Guidelines for management of glycogen storage disease type I – European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002;161 Suppl 1:S112–9.

    Article  PubMed  Google Scholar 

  22. Geberhiwot T, Alger S, Mckiernan P, Packard C, Caslake M, Elias E, Cramb R. Serum lipid and lipoprotein profile of patients with glycogen storage disease types I, III and IX. J Inherit Metab Dis. 2007;30:406.

    Article  PubMed  CAS  Google Scholar 

  23. Goldberg T, Slonim AE. Nutrition therapy for hepatic glycogen storage diseases. J Am Diet Assoc. 1993;93:1423–30.

    Article  PubMed  CAS  Google Scholar 

  24. Bruno C, Van Diggelen OP, Cassandrini D, Gimpelev M, Giuffre B, Donati MA, Introvini P, Alegria A, Assereto S, Morandi L, Mora M, Tonoli E, Mascelli S, Traverso M, Pasquini E, Bado M, Vilarinho L, Van Noort G, Mosca F, Dimauro S, Zara F, Minetti C. Clinical and genetic heterogeneity of branching enzyme deficiency (glycogenosis type IV). Neurology. 2004;63:1053–8.

    Article  PubMed  CAS  Google Scholar 

  25. Mckiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs. 2006;66:743–50.

    Article  PubMed  CAS  Google Scholar 

  26. Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis. 1998;21:|507–17.

    Article  PubMed  CAS  Google Scholar 

  27. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, Sarles J, De Baulny HO, Touati G. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008;31:81–7.

    Article  PubMed  CAS  Google Scholar 

  28. Mohan N, Mckiernan P, Preece MA, Green A, Buckels J, Mayer AD, Kelly DA. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr. 1999;158 Suppl 2:S49–54.

    Article  PubMed  Google Scholar 

  29. Matern D, Rinaldo P. Medium-chain acyl-coenzyme A dehydrogenase deficiency. In: Pagon RA, editor. Gene reviews. Seattle: University of Washington; 1993.

    Google Scholar 

  30. Iafolla AK, Thompson Jr RJ, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr. 1994;124:409–15.

    Article  PubMed  CAS  Google Scholar 

  31. Hayes B, Lynch B, O’keefe M, Monavari AA, Treacy EP. Long chain fatty acid oxidation defects in children: importance of detection and treatment options. Ir J Med Sci. 2007;176:189–92.

    Article  PubMed  CAS  Google Scholar 

  32. Olpin SE, Clark S, Andresen BS, Bischoff C, Olsen RK, Gregersen N, Chakrapani A, Downing M, Manning NJ, Sharrard M, Bonham JR, Muntoni F, Turnbull DN, Pourfarzam M. Biochemical, clinical and molecular findings in LCHAD and general mitochondrial trifunctional protein deficiency. J Inherit Metab Dis. 2005;28:533–44.

    Article  PubMed  CAS  Google Scholar 

  33. Wanders RJ, IJlst L, Van Gennip AH, Jakobs C, De Jager JP, Dorland L, Van Sprang FJ, Duran M. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid beta-oxidation. J Inherit Metab Dis. 1990;13:311–4.

    Article  PubMed  CAS  Google Scholar 

  34. Zschocke J, Penzien JM, Bielen R, Casals N, Aledo R, Pie J, Hoffmann GF, Hegardt FG, Mayatepek E. The diagnosis of mitochondrial HMG-CoA synthase deficiency. J Pediatr. 2002;140:778–80.

    Article  PubMed  CAS  Google Scholar 

  35. Morris AA, Olpin SE, Brivet M, Turnbull DM, Jones RA, Leonard JV. A patient with carnitine-acylcarnitine translocase deficiency with a mild phenotype. J Pediatr. 1998;132:514–6.

    Article  PubMed  CAS  Google Scholar 

  36. Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008;97:1420–5.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, Diaz GA, Seashore MR, Lee HS, Mccarter RJ, Krischer JP, Batshaw ML. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab. 2008;94:397–402.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  38. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007;356:2282–92.

    Article  PubMed  CAS  Google Scholar 

  39. Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res. 2009;66:96–101.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  40. Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, Bernard O, Jacquemin E. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010;51:1645–55.

    Article  PubMed  CAS  Google Scholar 

  41. Folmer DE, Van Der Mark VA, Ho-Mok KS, Oude Elferink RP, Paulusma CC. Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1. Hepatology. 2009;50:1597–605.

    Article  PubMed  CAS  Google Scholar 

  42. Strautnieks SS, Byrne JA, Pawlikowska L, Cebecauerova D, Rayner A, Dutton L, Meier Y, Antoniou A, Stieger B, Arnell H, Ozcay F, Al-Hussaini HF, Bassas AF, Verkade HJ, Fischler B, Nemeth A, Kotalova R, Shneider BL, Cielecka-Kuszyk J, Mcclean P, Whitington PF, Sokal E, Jirsa M, Wali SH, Jankowska I, Pawlowska J, Mieli-Vergani G, Knisely AS, Bull LN, Thompson RJ. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008;134:1203–14.

    Article  PubMed  CAS  Google Scholar 

  43. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis. 2010;30:134–46.

    Article  PubMed  CAS  Google Scholar 

  44. Englert C, Grabhorn E, Richter A, Rogiers X, Burdelski M, Ganschow R. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation. 2007;84:1361–3.

    Article  PubMed  Google Scholar 

  45. Setchell KD, Heubi JE. Defects in bile acid biosynthesis – diagnosis and treatment. J Pediatr Gastroenterol Nutr. 2006;43 Suppl 1:S17–22.

    Article  PubMed  CAS  Google Scholar 

  46. Heubi JE, Setchell KD, Bove KE. Inborn errors of bile acid metabolism. Semin Liver Dis. 2007;27:282–94.

    Article  PubMed  CAS  Google Scholar 

  47. Sundaram SS, Bove KE, Lovell MA, Sokol RJ. Mechanisms of disease: inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol. 2008;5:456–68.

    Article  PubMed  CAS  Google Scholar 

  48. Gonzales E, Gerhardt MF, Fabre M, Setchell KD, Davit-Spraul A, Vincent I, Heubi JE, Bernard O, Jacquemin E. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. Gastroenterology. 2009;137(1310–1320):e1311–3.

    Google Scholar 

  49. Clayton PT. Disorders of bile acid synthesis. J Inherit Metab Dis. 2011;34:593–604.

    Article  PubMed  CAS  Google Scholar 

  50. Setchell KDR, Heubi JE, Shah S, Levine JE, Suskind D, Al-Edreesi M, Potter C, Russell DW, O’Connell NC, Wolfe B, Jha P, Zhang W, Bove KE, Knisely A, Hofmann AF, Rosenthal P, Bull LN. Genetic defects in bile acid conjugation cause fat-soluble vitamin deficiency. Gastroenterology. 2013;144(5):945–55.e6; quiz e14–5.

    Article  PubMed  CAS  Google Scholar 

  51. Grabowski GA. Recent clinical progress in Gaucher disease. Curr Opin Pediatr. 2005;17:519–24.

    Article  PubMed  Google Scholar 

  52. Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, Harris CM, Kaplan P, Mengel E, Pocovi M, Vellodi A. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr. 2004;163:58–66.

    Article  PubMed  Google Scholar 

  53. Vanier MT, Wenger DA, Comly ME, Rousson R, Brady RO, Pentchev PG. Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients. Clin Genet. 1988;33:331–48.

    Article  PubMed  CAS  Google Scholar 

  54. Fink JK, Filling-Katz MR, Sokol J, Cogan DG, Pikus A, Sonies B, Soong B, Pentchev PG, Comly ME, Brady RO, et al. Clinical spectrum of Niemann-Pick disease type C. Neurology. 1989;39:1040–9.

    Article  PubMed  CAS  Google Scholar 

  55. Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Ashmead JW, Wenger DA. Niemann-pick disease type C in neonatal cholestasis at a North American Center. J Pediatr Gastroenterol Nutr. 2002;35:44–50.

    Article  PubMed  Google Scholar 

  56. Tolar J, Petryk A, Khan K, Bjoraker KJ, Jessurun J, Dolan M, Kivisto T, Charnas L, Shapiro EG, Orchard PJ. Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. Bone Marrow Transplant. 2009;43:21–7.

    Article  PubMed  CAS  Google Scholar 

  57. Du H, Cameron TL, Garger SJ, Pogue GP, Hamm LA, White E, Hanley KM, Grabowski GA. Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. J Lipid Res. 2008;49:1646–57.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  58. Leone L, Ippoliti PF, Antonicelli R. Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency. J Pediatr. 1991;119:1008–9.

    Article  PubMed  CAS  Google Scholar 

  59. Moser HW, Moser AB. Peroxisomal disorders: overview. Ann N Y Acad Sci. 1996;804:427–41.

    Article  PubMed  CAS  Google Scholar 

  60. Paker AM, Sunness JS, Brereton NH, Speedie LJ, Albanna L, Dharmaraj S, Moser AB, Jones RO, Raymond GV. Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial. Neurology. 2010;75:826–30.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  61. Wei H, Kemp S, Mcguinness MC, Moser AB, Smith KD. Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol. 2000;47:286–96.

    Article  PubMed  CAS  Google Scholar 

  62. Lee WS, Sokol RJ. Mitochondrial hepatopathies: advances in genetics and pathogenesis. Hepatology. 2007;45:1555–65.

    Article  PubMed  CAS  Google Scholar 

  63. Cormier-Daire V, Chretien D, Rustin P, Rotig A, Dubuisson C, Jacquemin E, Hadchouel M, Bernard O, Munnich A. Neonatal and delayed-onset liver involvement in disorders of oxidative phosphorylation. J Pediatr. 1997;130:817–22.

    Article  PubMed  CAS  Google Scholar 

  64. Holve S, Hu D, Shub M, Tyson RW, Sokol RJ. Liver disease in Navajo neuropathy. J Pediatr. 1999;135:482–93.

    Article  PubMed  CAS  Google Scholar 

  65. Narkewicz MR, Sokol RJ, Beckwith B, Sondheimer J, Silverman A. Liver involvement in Alpers disease. J Pediatr. 1991;119:260–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology, Hepatology, and Nutrition, Cincinnati Children’s Hospital Medical Center, MLC 2010, 3333 Burnet Ave, Cincinnati, OH, 45229-3026, USA

    James E. Squires MD

  2. Division of Gastroenterology, Hepatology, and Nutrition, Center for Clinical and Translational Science and Training (CCTST), Cincinnati Children’s Hospital Medical Center, MLC 2010, 3333 Burnet Ave, Cincinnati, OH, 45229-3026, USA

    James E. Heubi MD

Authors
  1. James E. Squires MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James E. Heubi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Heubi MD .

Editor information

Editors and Affiliations

  1. University of Washington School of Medicine, Seattle Children’s Hospital, Seattle, Washington, USA

    Karen F. Murray

  2. University of Washington School of Medicine, Seattle Children’s Hospital, Seattle, Washington, USA

    Simon Horslen

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Squires, J.E., Heubi, J.E. (2014). Metabolic Liver Disease: Part 1. In: Murray, K., Horslen, S. (eds) Diseases of the Liver in Children. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9005-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-9005-0_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-9004-3

  • Online ISBN: 978-1-4614-9005-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation